Harry Skip Kiil Sells 1,483 Shares of Medtronic (NYSE:MDT) Stock

Medtronic PLC (NYSE:MDT) EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Medtronic Price Performance

NYSE MDT opened at $92.19 on Friday. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The business’s fifty day moving average is $88.92 and its two-hundred day moving average is $85.03. The stock has a market capitalization of $117.92 billion, a P/E ratio of 22.71, a P/E/G ratio of 2.12 and a beta of 0.56. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The company’s revenue was up 13.7% compared to the same quarter last year. During the same period last year, the company posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts forecast that Medtronic PLC will post 5.97 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, September 25th. Medtronic’s payout ratio is presently 70.94%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on MDT shares. Needham & Company LLC reissued a “buy” rating on shares of Medtronic in a research report on Thursday. Truist Financial reaffirmed a “hold” rating and issued a $99.00 price objective (up from $86.00) on shares of Medtronic in a research note on Wednesday, September 2nd. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, September 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $92.00 target price on shares of Medtronic in a research note on Thursday, September 3rd. Finally, Wells Fargo & Company increased their target price on Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a report on Wednesday, September 2nd. Nineteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $103.92.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MDT. Gradient Investments LLC lifted its position in shares of Medtronic by 3.9% in the second quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company’s stock worth $38,842,000 after purchasing an additional 18,509 shares in the last quarter. Czech National Bank increased its position in shares of Medtronic by 4.7% in the second quarter. Czech National Bank now owns 365,443 shares of the medical technology company’s stock valued at $28,589,000 after acquiring an additional 16,292 shares during the last quarter. Cerity Partners LLC raised its holdings in Medtronic by 12.7% during the fourth quarter. Cerity Partners LLC now owns 791,015 shares of the medical technology company’s stock worth $75,988,000 after acquiring an additional 89,111 shares in the last quarter. National Pension Service boosted its position in Medtronic by 1.0% during the fourth quarter. National Pension Service now owns 2,982,411 shares of the medical technology company’s stock valued at $286,490,000 after purchasing an additional 28,269 shares during the last quarter. Finally, Verity & Verity LLC grew its stake in Medtronic by 5.1% in the second quarter. Verity & Verity LLC now owns 229,707 shares of the medical technology company’s stock valued at $17,970,000 after purchasing an additional 11,197 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reportedly raised its outlook again as demand for heart and cardiovascular devices continued to improve. Analysts also cited market-share gains in electrophysiology and stronger momentum across key franchises, supporting expectations for sustained growth. Medtronic Raises its Outlook Again as Heart Device Demand Keeps Climbing
• Positive Sentiment: The FDA cleared Medtronic’s LigaSure instrument for use with the Hugo robotic-assisted surgery system in the United States. The broader instrument portfolio could help Hugo compete for more procedures and expand Medtronic’s long-term surgical-robotics revenue. Medtronic Wins FDA Clearance for LigaSure Instrument on Hugo Robot
• Positive Sentiment: Needham said Medtronic’s deal with Cornerstone Robotics should complement the Hugo system. The partnership may strengthen Medtronic’s robotics capabilities and accelerate expansion of the platform. Medtronic’s Deal with Cornerstone Robotics to Complement Hugo Surgery System
• Positive Sentiment: Industry forecasts call for the global vascular-access-device market to grow at a 6.7% annual rate through 2031. Medtronic could benefit from rising demand for IV therapies and safer, antimicrobial and ultrasound-guided devices, although the report describes an industry opportunity rather than a company-specific announcement. Vascular Access Device Market Forecast
• Neutral Sentiment: Medtronic launched a share-exchange offer for up to approximately 225.4 million newly issued shares as part of its planned diabetes-business spin-off. The separation could sharpen strategic focus, but investors are weighing dilution, execution risks and the eventual ownership structure. Medtronic Advances Diabetes Spin-Off with Share Exchange
• Negative Sentiment: Executive Vice President Harry Kiil sold 1,483 shares worth about $139,000. The transaction reduced his position by 3.4%, but its relatively small size and his remaining substantial ownership limit the signal.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.